151 related articles for article (PubMed ID: 23463194)
21. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
[TBL] [Abstract][Full Text] [Related]
22. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
Ginindza TG; Sartorius B; Dlamini X; Östensson E
PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
[TBL] [Abstract][Full Text] [Related]
23. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias.
Paavonen J
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S3-9. PubMed ID: 18162244
[TBL] [Abstract][Full Text] [Related]
24. Reimbursed Costs of Management of Uterine Cervical Lesions in Poland--a Descriptive Analysis of Data from the National Health Fund and the Ministry of Health.
Nowakowski A; Śliwczyński A; Seroczyński P; Cybulski M; Teter Z
Cent Eur J Public Health; 2016 Jun; 24(2):163-8. PubMed ID: 27178030
[TBL] [Abstract][Full Text] [Related]
25. Long-Lasting Increased Risk of Human Papillomavirus-Related Carcinomas and Premalignancies After Cervical Intraepithelial Neoplasia Grade 3: A Population-Based Cohort Study.
Ebisch RMF; Rutten DWE; IntHout J; Melchers WJG; Massuger LFAG; Bulten J; Bekkers RLM; Siebers AG
J Clin Oncol; 2017 Aug; 35(22):2542-2550. PubMed ID: 28541790
[TBL] [Abstract][Full Text] [Related]
26. The annual costs associated with human papillomavirus types 6, 11, 16, and 18 infections in Finland.
Herse F; Reissell E
Scand J Infect Dis; 2011 Mar; 43(3):209-15. PubMed ID: 21171829
[TBL] [Abstract][Full Text] [Related]
27. Human papillomavirus testing in the prevention of cervical cancer.
Schiffman M; Wentzensen N; Wacholder S; Kinney W; Gage JC; Castle PE
J Natl Cancer Inst; 2011 Mar; 103(5):368-83. PubMed ID: 21282563
[TBL] [Abstract][Full Text] [Related]
28. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
[TBL] [Abstract][Full Text] [Related]
29. Spectrum of genital human papillomavirus infection in a female adolescent population.
Jamison JH; Kaplan DW; Hamman R; Eagar R; Beach R; Douglas JM
Sex Transm Dis; 1995; 22(4):236-43. PubMed ID: 7482107
[TBL] [Abstract][Full Text] [Related]
30. Epidemiological and economic burden of potentially HPV-related cancers in France.
Abramowitz L; Lacau Saint Guily J; Moyal-Barracco M; Bergeron C; Borne H; Dahlab A; Bresse X; Uhart M; Cancalon C; Catella L; Bénard S
PLoS One; 2018; 13(9):e0202564. PubMed ID: 30235216
[TBL] [Abstract][Full Text] [Related]
31. Resource Use and Cost of Treating Human Papillomavirus-Related Lesions in Japanese Women.
Mizukami A; Kaise T; Van Kriekinge G
Value Health Reg Issues; 2018 May; 15():56-62. PubMed ID: 29474179
[TBL] [Abstract][Full Text] [Related]
32. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
33. Model for predicting the burden and cost of treatment in cervical cancer and HPV-related diseases in Thailand.
Termrungruanglert W; Havanond P; Khemapech N; Lertmaharit S; Pongpanich S; Jirakorbchaipong P; Kitsiripornchai S; Taneepanichskul S
Eur J Gynaecol Oncol; 2012; 33(4):391-4. PubMed ID: 23091896
[TBL] [Abstract][Full Text] [Related]
34. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
Rambout L; Hopkins L; Hutton B; Fergusson D
CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
[TBL] [Abstract][Full Text] [Related]
35. [What should be known for the introduction of an HPV vaccine?].
Muñoz N; Jacquard AC
Presse Med; 2008 Oct; 37(10):1377-90. PubMed ID: 18786806
[TBL] [Abstract][Full Text] [Related]
36. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.
Östensson E; Hellström AC; Hellman K; Gustavsson I; Gyllensten U; Wilander E; Zethraeus N; Andersson S
Acta Obstet Gynecol Scand; 2013 Jul; 92(7):830-40. PubMed ID: 23530870
[TBL] [Abstract][Full Text] [Related]
37. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
[TBL] [Abstract][Full Text] [Related]
38. Cervical testing beyond the screening target age - A register-based cohort study from Finland.
Keltto N; Leivonen A; Pankakoski M; Sarkeala T; Heinävaara S; Anttila A
Gynecol Oncol; 2021 Aug; 162(2):315-321. PubMed ID: 34074539
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
Annemans L; Rémy V; Oyee J; Largeron N
Pharmacoeconomics; 2009; 27(3):231-45. PubMed ID: 19354343
[TBL] [Abstract][Full Text] [Related]
40. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.
Villa LL; Costa RL; Petta CA; Andrade RP; Paavonen J; Iversen OE; Olsson SE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; Krogh Gv; Lehtinen M; Malm C; Tamms GM; Giacoletti K; Lupinacci L; Railkar R; Taddeo FJ; Bryan J; Esser MT; Sings HL; Saah AJ; Barr E
Br J Cancer; 2006 Dec; 95(11):1459-66. PubMed ID: 17117182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
